NCT04936009 Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)
| NCT ID | NCT04936009 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-03-17 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2022-03-17 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized interventional study designed to evaluate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on neural and behavioral facets of social cognition in adults with autism spectrum disorder (ASD).
Eligibility Criteria
Inclusion Criteria: * Individuals between the ages of 18 and 40 years old with typical development or with a diagnosis of autism spectrum disorder. * Individuals able to participate in an EEG and eye-tracking experiment. Exclusion Criteria: * Participants reporting significant head trauma or serious brain illness. * Participants with major psychiatric illness that would preclude completion of study measures. * Participants with a history of serious medical illness, stroke, seizures, epileptiform EEG abnormalities, or family history of seizures. * Participants taking prescription medications that may affect cognitive processes under study. * Participants who have taken alcohol or recreational drugs within the preceding 24 hours. * Females of known/suspected pregnancy or who test positive on a pregnancy test. * Participants with a history of metalworking or injury by shrapnel or metallic objects are also excluded. * Participants with a history of prior TMS therapy or use of an investigational drug within 12 weeks of visit. * Participants with an IQ (intelligence quotient) below 80.
Contact & Investigator
James McPartland, PhD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT04936009 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04936009 currently recruiting?
Yes, NCT04936009 is actively recruiting participants. Contact the research team at n.wright@yale.edu for enrollment information.
Where is the NCT04936009 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT04936009 clinical trial?
NCT04936009 is sponsored by Yale University. The principal investigator is James McPartland, PhD at Yale University. The trial plans to enroll 60 participants.